Try a new search

Format these results:

Searched for:



Total Results:


Pharmacological interventions

Chapter by: Jummani, Rahil R; Shatkin, Jess P
in: Handbook of cognitive behavioral therapy for pediatric medical conditions by Friedberg, Robert D [Ed]; Paternostro, Jennifer K [Ed]
Cham, Switzerland: Springer Nature Switzerland AG; Switzerland, 2019
pp. 151-169
ISBN: 978-3-030-21682-5
CID: 4630412

New York University school-based telepsychiatry [Meeting Abstract]

Jummani, R
Objectives: Schools have long been recognized as major centers for provision of almost universally available health education and services. Seventy to 80 percent of children and adolescents who do receive mental healthcare do so in the school setting. School-based telepsychiatry is an underutilized modality to mitigate the limited access to mental health services for many youth, especially in rural communities. Methods: During the presentation, we will provide a review of the literature regarding use of school-based telepsychiatry. We will then review the design and implementation of the New York University (NYU) school-based telepsychiatry program in partnership with the New York State Office of Mental Health, highlighting key features. Results: We will report on the characteristics of the schools and patients participating in the NYU school-based telepsychiatry program. We will describe the experience of patients and trainees with school-based telepsychiatry, including impediments and successeswithassessment and treatment.Data will beprovided for school-based telepsychiatry services completed since the program was piloted. We will discuss demographics, diagnostic composition, and treatments conducted, as well as clinician and patient/family satisfaction with the modality. Conclusions: Schools are an ideal location for healthcare education and provision. Follow-up for mental health services in schools is much higher than in traditional community mental health facilities. School-based telepsychiatry is a modality that can be successfully implemented in underserved areas to significantly enhance the availability of needed mental health services for children and adolescents. Focus on education for psychiatric trainees in the modality and development of formal curricula is of outmost importance as the modality continues to gain increased utilization
ISSN: 1527-5418
CID: 2924162

ADHD and tic disorders

Chapter by: Jummani, Rahil; Coffey, Barbara J
pp. 343-352
CID: 2338702

Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study

Lyon, Gholson J; Samar, Stephanie; Jummani, Rahil; Hirsch, Scott; Spirgel, Arie; Goldman, Rachel; Coffey, Barbara J
OBJECTIVE: The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD). METHOD: Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI-Tics) at baseline and at follow-up. RESULTS: The mean (+/-SD) daily dose for aripiprazole was 4.5 +/- 3.0 mg. Mean (+/-SD) YGTSS Global Severity scores reduced from 61.82 +/- 13.49 at baseline to 33.73 +/- 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 +/- 7.74 at baseline to 16.73 +/- 7.54 at end point. Mean (+/-SD) CGI-Tic severity scores reduced from 4.45 +/- 0.52 (moderate-marked) at baseline to 3.18 +/- 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (91%) subjects achieved 1 ('very much improved') or 2 ('much improved') at end point. Most common adverse effects included appetite increase and weight gain in 5 subjects, mild extrapyramidal effects in 7 subjects, and headaches and tiredness/fatigue in 7 subjects; 1 subject experienced akathisia and muscle cramps. CONCLUSION: Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials
PMID: 20035580
ISSN: 1557-8992
CID: 105994

Hyperprolactinemia in an adolescent with psychotic disorder on risperidone [Case Report]

Jummani, Rahil; Coffey, Barbara J
PMID: 20035598
ISSN: 1557-8992
CID: 105995

Treatment of juvenile-onset bipolar disorder in a child with Turner's syndrome [Case Report]

Anam, Seeba; Jummani, Rahil; Coffey, Barbara; Wieland, Natalie
PMID: 17630874
ISSN: 1044-5463
CID: 73866

Loxapine treatment in an autistic child with aggressive behavior: therapeutic challenges

Reinblatt, Shauna P; Abanilla, P Karen; Jummani, Rahil; Coffey, Barbara
PMID: 17069553
ISSN: 1044-5463
CID: 137977

Advanced pediatric psychopharmacology [Case Report]

Vito, Jose; Jummani, Rahil; Coffey, Barbara
PMID: 16958576
ISSN: 1044-5463
CID: 68402

Sydenham chorea

Jummani, R; Okun, M
PMID: 11176972
ISSN: 0003-9942
CID: 68404

Antiphospholipid- associated recurrent chorea and ballism in a child with cerebral palsy [Case Report]

Okun, M S; Jummani, R R; Carney, P R
We present the case of a 9-year-old female with cerebral palsy and repeated episodes of ballism associated with antiphospholipid and anticardiolipin antibodies. She was treated unsuccessfully with varying medications, including neuroleptics, anticholinergics, antiepileptics, dopamine, dopamine agonists, and monoamine oxidase inhibitors. Intravenous immunoglobulin and corticosteroids led to resolution of the movements. We postulate an immune mechanism of disease for ballism associated with antiphospholipid and anticardiolipin antibodies
PMID: 10963973
ISSN: 0887-8994
CID: 68403